The ŕise of 46% to Paradigm Pharma yesterday for promising results of it's Osteoarthritis drug is another indication of the possibilities that IMU has in front of it.
This is a company with no revenue and one could say a medium sized market to sell into, in contrast we have seen the huge potential that IMU have in both the blood cancer and solid cancer market.
Sadly none of this potential is recognised in the investor market and in fact it has been seen as a good shorting prospect for quite a few months now, sitting at around 6%.
MSB was also a useful shorting stock for many shorters and it must be said they were very successful at picking the right times to get in.
Thankfully this çan be turned around quickly and when it does there appears to be no holding back for the bulls as they feast on those low share prices like ravenous dogs.
Smart investors have been buying Imu shares up quietly and will continue to do so while vatigued shareholders make the hard decision to get out and recover some of their original investment, or in some cases those that purchased 12 months ago make a small profit and move on to faster growing profits.
I will hold on with my holding as I remain confident that this company is on the right track and they have the right people behind some exciting IP.
DYOR opinion only
IMU Price at posting:
3.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)